ArticleAnalytical and bioanalytical chemistry2026
High-affinity recombinant antibodies enable a sensitive MRGPRX2-specific ELISA for detecting allergic rhinitis and chronic spontaneous urticaria.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mas-related G-protein-coupled receptor X2 (MRGPRX2) plays a critical role in mast cell activation and the mediation of pseudo-allergic reactions, and its detection in peripheral blood is important for investigating mast cell-related disorders such as allergic rhinitis (AR), chronic spontaneous urticaria (CSU), and asthma. However, existing assays based on polyclonal and hybridoma-derived monoclonal antibodies suffer from limitations in accuracy, reproducibility, and standardization, highlighting the need for alternative antibody strategies. In this study, animals were immunized with a rationally selected MRGPRX2 peptide identified using the IEDB Analysis Resource, and sequence-defined recombinant monoclonal antibodies were generated. A sandwich ELISA was subsequently established and validated using serum samples from patients with AR, CSU, and healthy controls (Chinese Clinical Trial Registry: ChiCTR2400082024, ChiCTR2400094130). The peptide spanning residues 289-330 was identified as an optimal immunogen, and six recombinant antibodies were obtained, among which optimal capture-detection pairs exhibited high affinity as confirmed by surface plasmon resonance and Western blot analysis. The developed ELISA demonstrated excellent linearity over the concentration range of 1.5625-200 ng/mL (y = 82.772x - 9.6566, R
Indexed as
Identifiers
41686245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.